Juliana Pessoa Rivello de Azevedo

Real-world outcomes of CD34⁺ mobilization and early autologous hematopoietic stem cell transplantation recovery after daratumumab-based induction

INTRODUCTION: Daratumumab, an Anti-CD38 monoclonal antibody, is now widely used in frontline induction for transplant-eligible multiple myeloma. Although highly effective, concerns remain regarding its potential impact on CD34⁺ stem cell mobilization and early outcomes after auto...